the MAPUSE model
Diagnostic TestUsing the MAPUSE model to predict MVI status before surgical resection for HCC patients
NCT Number: NCT06760494
An artificial intelligence (AI) model to predict MVI of HCC using contrast-enhanced ultrasound was constructed. This model also has biological explainability. The investigators named it as MAPUSE (MVI AI prediction via contrast-enhanced ultrasound with explainability).
The goal of MAPUSE study is to prospectively test the performance of MAPUSE model on MVI prediction and its biological correlation in different geographical areas of China.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
The presence of microvascular invasion (MVI) in hepatocellular carcinoma (HCC) is a critical prognostic indicator, but its preoperative diagnosis remains challenging. Contrast-enhanced ultrasound (CEUS), with its dynamic microvascular imaging capability, holds promise in prediction of MVI.
The investigators constructed an artificial intelligence (AI) model to predict MVI using contrast-enhanced ultrasound. This model also has biological explainability. We named it as MAPUSE (MVI AI prediction via contrast-enhanced ultrasound with explainability).
The goal of MAPUSE study is to prospectively test the performance of MAPUSE model on MVI prediction and its biological correlation in different geographical areas of China.
The performance of MAPUSE is to be tested in two prospective testing cohorts from two centers in southern and northern China. Before surgery, patient CEUS videos will be collected and analysed by MAPUSE model to generate an MVI risk score. According to the postoperative pathological diagnosis of MVI (golden criterion), the result of MAPUSE will be evaluated. Parameters include area under curve (AUC), accuracy (ACC), sensitivity, specificity and F1-score.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Using the MAPUSE model to predict MVI status before surgical resection for HCC patients
Time frame: From preoperative enrollment to the postoperative confirmation of pathological diagnosis (7-15 days postopertively)
the area under operating characteristic curves (AUC) to evaluate the performance of MAPUSE model in predicting MVI in HCC patients
Time frame: From preoperative enrollment to the postoperative confirmation of pathological diagnosis (7-15 days postopertively)
The ratio of the number of samples correctly predicted by the model to the total number of samples
Time frame: From preoperative enrollment to the postoperative confirmation of pathological diagnosis (7-15 days postopertively)
Proportion of all patients without MVI who are predicted negative by MAPUSE
Time frame: From preoperative enrollment to the postoperative confirmation of pathological diagnosis (7-15 days postopertively)
The proportion of patients with MVI that MAPUSE correctly identifies
Chinese PLA General Hospital
Other
Prediction of Microvascular Invasion in HCC Using Spatiotemporal Radiomics of Contrast-enhanced Ultrasound: a Deep Learning Model With Transcriptomics Correlation
Acronym: MAPUSE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05665348
Adenocarcinoma, Carcinoma
Amiens, France
View Trial DetailsNCT06631326
Adenocarcinoma, BCLC Stage C Hepatocellular Carcinoma
Shenyang, Liaoning, China
View Trial DetailsNCT07184424
Adenocarcinoma, Carcinoma
Beijing, China
View Trial DetailsNCT06991907
125I Seeds Implantation, Adenocarcinoma
Nanchang, Jiangxi, China
View Trial Details